|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600122549 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-15 10:16:39 |
|
注册时间: Date of Registration: |
2026-04-15 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于平原心肺运动试验的急性高原病预测模型开发与验证 |
|
Public title: |
Development and Validation of a Prediction Model for Acute Mountain Sickness Based on Plain Cardiopulmonary Exercise Test |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于平原心肺运动试验的急性高原病预测模型开发与验证 |
|
Scientific title: |
Development and Validation of a Prediction Model for Acute Mountain Sickness Based on Plain Cardiopulmonary Exercise Test |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
尚昀林 |
研究负责人: |
尚昀林 |
|
Applicant: |
Shang Yunlin |
Study leader: |
Shang Yunlin |
|
申请注册联系人电话: Applicant telephone: |
+86 18521317271 |
研究负责人电话:
Study leader's |
+86 21 3773 0011 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
shang1994427@foxmail.com |
研究负责人电子邮件: Study leader's E-mail: |
shang1994427@foxmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市松江区光星路2209号 |
研究负责人通讯地址: |
上海市松江区光星路2209号 |
|
Applicant address: |
2209,Guangxing Road,Songjiang District,Shanghai |
Study leader's address: |
2209,Guangxing Road,Songjiang District,Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
同济大学附属养志康复医院 |
||
|
Applicant's institution: |
Yangzhi Rehabilitation Hospital,Tongji University |
||
|
研究负责人所在单位: |
上海市养志康复医院 |
||
|
Affiliation of the Leader: |
Shanghai Yangzhi Rehabilitation Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
养志伦审字〔2026〕002号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海市养志康复医院(上海市阳光康复中心)医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-03-10 00:00:00 | ||
|
伦理委员会联系人: |
王涛 |
||
|
Contact Name of the ethic committee: |
Wang Tao |
||
|
伦理委员会联系地址: |
上海市松江区光星路2209号 |
||
|
Contact Address of the ethic committee: |
2209,Guangxing Road,Songjiang District,Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 37730011 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
13644870352@163.com |
|
研究实施负责(组长)单位: |
上海市养志康复医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Yangzhi Rehabilitation Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市松江区光星路2209号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2209,Guangxing Road,Songjiang District,Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
阳光临床研究培育项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Yangguang Clinical Research Cultivation Program |
||||||||||||||||||||||
|
研究疾病: |
急性高原病 |
||||||||||||||||||||||
|
Target disease: |
Acute Mountain Sickness |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
本研究旨在通过结合地面心肺运动试验(Normoxic Cardiopulmonary Exercise Test, N-CPET)与低压氧舱模拟高原环境,结合机器学习技术,构建一个预测个体对高原反应剧烈程度或急性高原病(Acute Mountain Sickness, AMS)风险的模型。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study aims to integrate normoxic cardiopulmonary exercise testing (N-CPET) conducted at ground level with simulated high?altitude exposure via a hypobaric hypoxia chamber, and employ machine learning techniques to develop a model for predicting the severity of individual high?altitude responses or the risk of acute mountain sickness (AMS). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.受试者为年龄 18-40 岁的健康成年人, 2.为平原常住居民(居住海拔<1500 米,近 6 个月未进入>2500 米高原), 3.无吸烟、酗酒史,既往体健、无其他重大疾病史(心脑血管、呼吸系统), 4.无高原病(脑水肿等)病史, 5.目前没有使用影响心肺疾病的药物。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Subjects are healthy adults aged 18-40 years, 2. Permanent residents of plains (living at an altitude <1500 meters, not having entered areas above 2500 meters in the past 6 months), 3. No history of smoking or alcohol abuse, previously healthy, with no other major disease history (cardiovascular, cerebrovascular, respiratory systems), 4. No history of high-altitude illness (such as cerebral edema), 5. Currently not using medications that affect cardiovascular or pulmonary diseases. |
||||||||||||||||||||||
|
排除标准: |
1.有重大疾病史的; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.With a history of major diseases; 2.With a history of severe acute mountain sickness; 3.Unable or unwilling to cooperate with the study procedures; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-12-01 00:00:00至 To 2027-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-04-15 00:00:00 至 To 2027-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not shared. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据管理: 本研究为一项前瞻性、单组、干预性研究,采用标准化数据管理流程,确保数据质量与完整性。 ①病例报告表设计 采用结构化电子病例报告表,包含以下模块: a.筛选与基线信息 b.心肺运动试验(CPET)数据 c.低压氧舱干预期生理指标与症状评分(LLS) d.不良事件与严重不良事件记录 e.研究完成情况与中止记录 ②数据清理与质控 a.专人执行逻辑核查(如数值范围、时间顺序、必填项)。 b.每周由数据管理员核查异常值与缺失数据,并溯源至原始记录。 c.每月召开数据审核会议,由项目负责人与临床研究员共同审议数据质量。 ③数据锁定与移交 a.研究结束后,数据库经最终核查、疑问清理后锁定。 b.锁定后生成不可更改的版本,移交至统计分析人员。 c.所有数据变更均留有审计轨迹。 数据安全与隐私保护: ①数据脱敏处理 1)脱敏范围:受试者姓名、身份证号、联系电话、家庭住址、银行卡号、就诊卡号等个人标识信息; 2)脱敏规则:受试者入组后立即分配唯一研究编号,所有研究数据均以研究编号标识,去除直接个人标识信息; 3)执行要求:由 2 名数据管理员独立完成脱敏处理,交叉核对;仅项目负责人与指定研究者可查阅研究编号与受试者个人信息的映射表,映射表单独加密存储。 ②数据加密管理 1)电子数据加密:所有研究电子数据采用 AES-256 对称加密算法加密存储;数据传输采用 SSL/TLS 协议加密,确保传输安全; 2)权限管理:建立三级数据访问权限体系:① 一级权限(项目负责人):可查阅、修改全部数据;② 二级权限(临床研究者):仅可查阅、录入本人负责的受试者数据;③ 三级权限(统计分析人员):仅可查阅脱敏后的分析数据集,无修改权限;所有权限操作均留存完整日志,可溯源审计。 ③数据存储规范 1)存储介质:原始纸质数据存放于上海市养志康复医院课题组档案管理柜,;电子数据存储于课题组科研专用加密电脑,同时完成异地双备份,备份数据与主数据物理隔离; 2)存储期限:所有研究数据自研究结束之日起,至少保存 30 年,符合《涉及人的生命科学和医学研究伦理审查办法》存档要求; 3)存储环境:纸质档案具备防火、防潮、防虫、防盗措施;电子数据服务器设置防火墙、入侵检测系统,定期开展安全漏洞扫描与病毒查杀。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data Management:This is a prospective, single-arm, interventional study that adopts a standardized data management process to ensure data quality and integrity.1. Case Report Form DesignA structured electronic case report form (eCRF) will be used, consisting of the following modules:a. Screening and baseline informationb. Cardiopulmonary exercise test (CPET) datac. Physiological indicators and symptom scores (LLS) during hypobaric hypoxia chamber interventiond. Records of adverse events (AEs) and serious adverse events (SAEs)e. Records of study completion and discontinuation2. Data Cleaning and Quality Controla. Dedicated staff will perform logical checks (e.g., value ranges, chronological order, mandatory fields).b. Data managers will review outliers and missing data weekly and trace them back to original records.c. A data review meeting will be held monthly, where the principal investigator and clinical researchers will jointly evaluate data quality.3. Data Lock and Transfera. Upon completion of the study, the database will be locked after final verification and query resolution.b. An unalterable version will be generated after locking and transferred to statisticians for analysis.c. A complete audit trail will be maintained for all data modifications. Data Security and Privacy Protection:1. Data De-identificationScope of de-identification: personally identifiable information (PII) including subjects’ name, ID number, telephone number, residential address, bank card number, medical record number, etc.De-identification rules: each subject will be assigned a unique study identification number immediately after enrollment; all study data will be identified by this number, with direct PII removed.Implementation requirements: de-identification will be completed independently and cross-checked by two data managers. Only the principal investigator and designated researchers may access the mapping table between study identification numbers and subjects’ PII, which will be stored separately in encrypted form.2. Data Encryption and Access ManagementElectronic data encryption: all electronic study data will be stored encrypted using the AES-256 symmetric encryption algorithm; data transmission will be encrypted via SSL/TLS protocol to ensure transmission security.Authority management: a three-tier data access authority system will be established:Tier 1 (Principal Investigator): full access to view and modify all data.Tier 2 (Clinical Researchers): only view and enter data for subjects under their responsibility.Tier 3 (Statisticians): only access de-identified datasets for analysis, with no data modification rights.Complete logs of all authority operations will be retained for traceability and auditing.3. Data Storage SpecificationsStorage media: original paper data will be stored in the filing cabinet of the research group at Shanghai Yangzhi Rehabilitation Hospital. Electronic data will be stored on a dedicated encrypted research computer, with dual off-site backups that are physically isolated from the primary data.Storage period: all study data will be preserved for at least 30 years from the date of study completion, in compliance with the archiving requirements of the Measures for Ethical Review of Life Science and Medical Research Involving Humans.Storage environment: paper archives will be protected by fireproof, moisture-proof, insect-proof and anti-theft measures. Electronic data servers will be equipped with firewalls and intrusion detection systems, with regular security vulnerability scans and virus detection and removal. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |